Alterity Therapeutics Presents Positive Phase 2 Data for ATH434 in MSA at AAN Meeting
Summary
Alterity Therapeutics announced new analysis from its ATH434 Phase 2 trial, demonstrating clinical efficacy in Multiple System Atrophy patients and reinforcing its profile for Phase 3.
Key Events
-
Positive Phase 2 Data Presented
Alterity Therapeutics presented new analysis from its ATH434 Phase 2 trial at the American Academy of Neurology Annual Meeting, demonstrating clinical efficacy in Multiple System Atrophy (MSA) patients.
-
Functional Decline Reduced
The analysis showed ATH434 reduced functional decline versus placebo at Week 52 on the newly described MuSyCA composite scale, which is designed to improve detection of disease progression.
-
Efficacy Reinforced for Phase 3
The observed effects on daily function and neurological examination are consistent with previously reported activity, reinforcing ATH434's clinical profile ahead of Phase 3 engagement with regulators.
Analysis
This filing provides the detailed positive clinical data from the previously announced late-breaker presentation at the American Academy of Neurology Annual Meeting. The new analysis using the MuSyCA composite scale showed ATH434 reduced functional decline in MSA patients, consistent with prior findings. This reinforces the drug's efficacy and strengthens the company's position as it prepares for Phase 3 regulatory engagement, which is critical for a development-stage biotech.
At the time of this filing, ATHE was trading at $5.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.5M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.